Targeted therapy combined with neoadjuvant chemoradiotherapy for locally advanced rectal cancer

doi:10.3760/cma.j.issn.1673-422X.2014.02.011

Abstract

Abstract: Neoadujuvant chemoradiotherapy combined with total mesorectal excision (TME) is the standard treatment modality for locally advanced rectal cancer (LARC). Targeted drugs in LARC neoadjuvant therapy are well tolerated and safety, but compared with conventional neoadjuvant chemoradiotherapy, the pathologic complete response (pCR) rate is not increased. Large sample randomized controlled trials are needed to confirm the effects of targeted drugs in the neoadjuvant treatment of LARC.

Key words: Rectal neoplasms, Receptor, epidermal growth factor, Receptors, vascular endothelial growth factor, Neoadjuvant therapy

Zhou Ning, Zhu Yuan, Luo Jialin. Targeted therapy combined with neoadjuvant chemoradiotherapy for locally advanced rectal cancer[J]. Journal of International Oncology, 2014, 41(2): 113-116.

References

［1］ Huerta S. New directions in the preoperative management of adenocarcinoma of the rectum［J］. Crit Rev Oncog, 2012, 17(4)：393-396. ［2］ Hong YS, Kim DY, Lim SB, et al. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: longterm results of a Phase Ⅱ study［J］. Int J Radiat Oncol Biol Phys, 2011, 79(4)：1171-1178. ［3］ Bertolini F, Chiara S, Bengala C, et al. Neoadjuvant treatment with singleagent cetuximab followed by 5FU, cetuximab, and pelvic radiotherapy: a phase Ⅱ study in locally advanced rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2009, 73 (2)：466-472. ［4］ Velenik V, Ocvirk J, Oblak I, et al. A phase Ⅱ study of cetuximab, capecitabine and radiotherapy in neoadjuvant treatment of patients with locally advanced resectable rectal cancer［J］. Eur J Surg Oncol, 2010, 36(3)：244-250. ［5］ Sun PL, Li B, Ye QF. Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase Ⅱ study［J］. Int J Colorectal Dis, 2012, 27(10)：1325-1332. ［6］ Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase Ⅱ clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with highrisk rectal cancer (EXPERTC)［J］. J Clin Oncol, 2012, 30(14)：1620-1627. ［7］ Kim SY, Hong YS, Kim DY, et al. Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase Ⅱ study［J］. Int J Radiat Oncol Biol Phys, 2011, 81(3)：677-683. ［8］ Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX4 as firstline treatment for metastatic colorectal cancer: the OPUS study［J］. Ann Oncol, 2011, 22(7)：1535-1546. ［9］ Debucquoy A, Haustermans K, Daemen A, et al. Molecular response to cetuximab and efficacy of preoperative cetuximabbased chemoradiation in rectal cancer［J］. J Clin Oncol, 2009, 27(17)：2751-2757. ［10］ Erben P, Strbel P, Horisberger K, et al. KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximabbased chemoradiotherapy in locally advanced rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2011, 81(4)：1032-1038. ［11］ Zhu Y, Liu LY, Luo JL, et al. Preoperative chemoradiation with nimotuzumab and capecitabine in patients with locally advanced rectal cancer: a phase Ⅱ study［J］. J Clin Oncol 30, 2012 (suppl: abstr e14049). ［12］ Czito BG, Willett CG, Bendell JC, et al. Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase Ⅰ trial results［J］. J Clin Oncol, 2006, 24(4)：656-662. ［13］ Valentini V, De Paoli A, Gambacorta MA, et al. Infusional 5fluorouracil and ZD1839 (GefitinibIressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase Ⅰ and Ⅱ Trial (1839IL/0092)［J］. Int J Radiat Oncol Biol Phys, 2008, 72(3)：644-649. ［14］田源, 蔡欣, 刘基巍. 结肠直肠癌的分子靶向治疗进展［J］. 癌症进展, 2010, 8(2)：151-155, 179. ［15］ Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase Ⅱ study［J］. J Clin Oncol, 2009, 27(18)：3020-3026. ［16］ Crane CH, Eng C, Feig BW, et al. Phase Ⅱ trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer［J］. Int J Radiat Oncol Biol Phys, 2010, 76(3)：824-830. ［17］ Nogué M, Salud A, Vicente P, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabinebased chemoradiotherapy in magnetic resonance imagingdefined poorprognosis locally advanced rectal cancer: the AVACROSS study［J］. Oncologist, 2011, 16(5)：614-620. ［18］ Velenik V, Ocvirk J, Music M, et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an openlabel phase Ⅱ study［J］. Radiat Oncol, 2011, 6：105. ［19］ Kennecke H, Berry S, Wong R, et al. Preoperative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase Ⅱ trial［J］. Eur J Cancer, 2012, 48(1)：37-45. ［20］ Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase Ⅱ trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecanrefractory colorectal cancer: the BOND2 study［J］. J Clin Oncol, 2007, 25(29)：4557-4561. ［21］ Tol J, Koopman M, Rodenburg CJ, et al. A randomised phase Ⅲ study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in firstline advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity［J］. Ann Oncol, 2008, 19(4)：734-738. ［22］ Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase ⅢB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer［J］. J Clin Oncol, 2009, 27(5)：672680. ［23］ Wong NS, Fernando NH, Nixon AB ,et al. A phase Ⅱ study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer［J］. Anticancer Res, 2011, 31(1)：255-261.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[5]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[6]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[7]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[8]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[9]	Xu Fang, Zhu Wentian. Progress in adjuvant therapy of hepatocellular carcinoma complicated with microvascular invasion [J]. Journal of International Oncology, 2023, 50(5): 304-309.
[10]	Zeng Liwu, Du Yuqiang, Zhang Peng, Tao Kaixiong. Progress in imaging evaluation of lateral lymph node metastasis in rectal cancer [J]. Journal of International Oncology, 2023, 50(4): 248-251.
[11]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[12]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[13]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[14]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[15]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.